Forensic Analysis · Industrials / Manufacturing / Defense · as of Sep 25, 2026
908 Devices Inc. (MASS)
A forensic read on 908 Devices Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
8.8
Distress distance
Watch
Earnings quality
5
Forensic signals
-11.3
P / E (ttm)
13.6%
ROE
$452M
Market cap
0.00%
Dividend yield
17.7%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
908 Devices Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 8.8, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-36.4%
FY2025
Return on invested capital.Return on invested capital is -36.4% in the latest fiscal year and rising across FY2023–FY2025 from -56.9%. After-tax operating profit was ($34M) in FY2023 and ($31M) in FY2025, with operating income at -85.1% of revenue in FY2023, -120.2% in FY2024 and -70.1% in FY2025. The capital base behind it grew +44% across FY2023–FY2025, from $59M to $85M, and the return did not fall doing it, so the dollars added over that window earned at least the -56.9% the older base was already earning. FY2024's operating profit carried a $41M goodwill write-off and a $710,000 restructuring charge that alone took about 36.2 points off that year's return; FY2024 sits between the two ends of FY2023–FY2025, so the charge shapes the path between them without moving the change across it.
+5.5%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +11% over the last 2 years to FY2025 (+5.5%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~5.5% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~10%.
18% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 18% of revenue in FY2025 — about $0.27 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 5.5% a year and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
74d DSO
Key fundamentals
Latest Revenue$56.2M
Revenue Growth YoY+17.7%
Revenue CAGR (2yr)+5.8%
Net Margin34.7%
Free Cash Flow-$24.6M
Return on Equity13.6%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from 908 Devices Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 25, 2026. Forensic signals flag probability, not certainty.
908 Devices Inc. (MASS) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 68 to 74 days FY2024→FY2025 (receivables +28% vs revenue +18%). Receivables are creeping up relative to sales. Across FY2023–FY2025 the day count ran 65 → 68 → 74 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter. Deferred revenue was roughly flat (-16%) over the same period, which doesn't corroborate a benign upfront-billing explanation for the receivables build. Measured against the same quarter twelve months earlier — like-for-like on the calendar, so an ordinary seasonal build cannot produce it — receivables took longer to collect in 3 consecutive quarters (Dec 2025 +3, Mar 2026 +13, Jun 2026 +23 days). In the latest of them the receivable balance grew +89% against sales +23%, so more of a quarter's billings were still outstanding at the period end than a year earlier — money the company has recognized and not yet been paid. Both figures are measured on period-end balances rather than the beginning-plus-ending average, because averaging needs the balance a year before every reading — FY2024's opening balance is on file, but across the 3 fiscal years read here (FY2023–FY2025) the average yields only 2 day counts (1 step), too few to tell a climb from one year's move.
$41M
FY2024–FY2024
Goodwill impairments.Took $41M of goodwill writedowns across 1 year (FY2024 ($41M)). Writedowns mean past acquisitions underperformed what was paid for them.